Akira Miyazaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akira Miyazaki has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Masashi Akiyama
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Japan
10 shared publications - Takuya Takeichi
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
7 shared publications - Yoshinao Muro
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
7 shared publications - Tomoki Taki
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
4 shared publications - Haruka Koizumi
Department of Dermatology Toyota Memorial Hospital Toyota Aichi Japan
3 shared publications - Mariko Ogawa-Momohara
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
3 shared publications
Latest Publications
- 10 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7)
Paraspinal Muscle Atrophy on Chest CT as a Prognostic Marker for Anti‐Aminoacyl‐ tRNA Synthetase Antibody‐Positive Myositis
- 10 May 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7)
Paraspinal Muscle Atrophy on Chest CT as a Prognostic Marker for Anti‐Aminoacyl‐ tRNA Synthetase Antibody‐Positive Myositis
- 25 February 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (2)
Independent BRAF Fusion Genes Cause Pigmented Nevi in Ring Chromosome 7 Syndrome
- 25 February 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (2)
Independent BRAF Fusion Genes Cause Pigmented Nevi in Ring Chromosome 7 Syndrome
- 14 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1)
MVD ‐Nonsyndromic Epidermal Differentiation Disorder With a Previously Unreported Splice Variant in MVD Followed by Bullous Pemphigoid
- 14 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1)
MVD ‐Nonsyndromic Epidermal Differentiation Disorder With a Previously Unreported Splice Variant in MVD Followed by Bullous Pemphigoid
- Open Access
- 6 February 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 556-558
Infiltration of M2a macrophages is predominant in genital verruciform xanthoma
- 6 February 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 556-558
Open AccessInfiltration of M2a macrophages is predominant in genital verruciform xanthoma
- 23 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (10) , e340-e341
Case of monomicrobial necrotizing fasciitis caused by extended‐spectrum β‐lactamase–producing Citrobacter freundii
- 23 April 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (10) , e340-e341
Case of monomicrobial necrotizing fasciitis caused by extended‐spectrum β‐lactamase–producing Citrobacter freundii
- 16 February 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (7) , e227-e228
Panniculitis on the trunk as a possible characteristic feature of anti‐SAE1/2 antibody‐positive dermatomyositis: A possible cutaneous manifestation of treatment resistance
- 16 February 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (7) , e227-e228
Panniculitis on the trunk as a possible characteristic feature of anti‐SAE1/2 antibody‐positive dermatomyositis: A possible cutaneous manifestation of treatment resistance
- 25 October 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (2) , e85-e86
Whole‐exome sequencing reveals a retinitis pigmentosa‐causative PRPH2 variant as a secondary finding in a patient with pseudoxanthoma elasticum
- 25 October 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (2) , e85-e86
Whole‐exome sequencing reveals a retinitis pigmentosa‐causative PRPH2 variant as a secondary finding in a patient with pseudoxanthoma elasticum
- 21 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (8) , E276-E277
Extremely mild dominant dystrophic epidermolysis bullosa: Genotype information from whole‐exome sequencing of salivary gDNA predicts disease severity
- 21 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (8) , E276-E277
Extremely mild dominant dystrophic epidermolysis bullosa: Genotype information from whole‐exome sequencing of salivary gDNA predicts disease severity
- 19 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (8) , 779-782
Darier disease successfully treated with a topical agent containing vitamin A (retinyl palmitate), vitamin E, and urea
Darier disease (DD), also called keratosis follicularis, is an autosomal dominant hereditary keratinization disorder that manifests as keratotic papules with plaques in seborrheic areas. There are no validated curative treatments for DD, with the majority of cases treated symptomatically. We report the efficacy of a topical over‐the‐counter agent which contains retinyl palmitate, vitamin E, and urea for a patient with DD. A 13‐year‐old girl had brown papules on her scalp, neck, shoulders, and axillae since entering elementary school. A skin biopsy revealed hyperkeratosis, suprabasal acantholysis, and dyskeratosis manifested as corps ronds and grains in the epidermis. Sanger sequencing found the previously reported heterozygous mutation c.1484C>T in ATP2A2. The application of an over‐the‐counter topical agent containing retinyl palmitate 2750 μg/g (5000 IU/g), tocopheryl acetate 20 mg/g, urea 200 mg/g, and monoammonium glycyrrhizinate 5 mg/g twice daily for 2 months improved the papules without serious adverse events. Oral or topical aromatic vitamin A analogs (retinoids) are often used to treat DD. However, several adverse events are associated with retinoid treatment, and many patients only undergo their intermittent use or discontinue the treatments. Retinyl palmitate is more stable and has a lower irritative profile than other retinoic acids. When applied topically, however, retinyl palmitate cannot penetrate the skin as well as retinol can. Some reports have noted that vitamin E increases the biological availability of vitamin A and that urea helps mechanical percutaneous drug delivery. Our case suggests that retinyl palmitate has a sufficient therapeutic effect when combined with vitamin E and urea. In conclusion, we propose that topical agents containing retinyl palmitate, vitamin E, and urea might have a satisfactory effect on the skin lesions of DD patients, without the serious risks of adverse events.
- 19 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (8) , 779-782
Darier disease successfully treated with a topical agent containing vitamin A (retinyl palmitate), vitamin E, and urea
Darier disease (DD), also called keratosis follicularis, is an autosomal dominant hereditary keratinization disorder that manifests as keratotic papules with plaques in seborrheic areas. There are no validated curative treatments for DD, with the majority of cases treated symptomatically. We report the efficacy of a topical over‐the‐counter agent which contains retinyl palmitate, vitamin E, and urea for a patient with DD. A 13‐year‐old girl had brown papules on her scalp, neck, shoulders, and axillae since entering elementary school. A skin biopsy revealed hyperkeratosis, suprabasal acantholysis, and dyskeratosis manifested as corps ronds and grains in the epidermis. Sanger sequencing found the previously reported heterozygous mutation c.1484C>T in ATP2A2. The application of an over‐the‐counter topical agent containing retinyl palmitate 2750 μg/g (5000 IU/g), tocopheryl acetate 20 mg/g, urea 200 mg/g, and monoammonium glycyrrhizinate 5 mg/g twice daily for 2 months improved the papules without serious adverse events. Oral or topical aromatic vitamin A analogs (retinoids) are often used to treat DD. However, several adverse events are associated with retinoid treatment, and many patients only undergo their intermittent use or discontinue the treatments. Retinyl palmitate is more stable and has a lower irritative profile than other retinoic acids. When applied topically, however, retinyl palmitate cannot penetrate the skin as well as retinol can. Some reports have noted that vitamin E increases the biological availability of vitamin A and that urea helps mechanical percutaneous drug delivery. Our case suggests that retinyl palmitate has a sufficient therapeutic effect when combined with vitamin E and urea. In conclusion, we propose that topical agents containing retinyl palmitate, vitamin E, and urea might have a satisfactory effect on the skin lesions of DD patients, without the serious risks of adverse events.